Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amazon

Bank of America

Biogen

Bank of New York Mellon

Blackrock Inc

Comcast

CME Group

Compass Minerals

Salesforce

Corteva Inc

Disney

Domino's Pizza

Ecolab

Equifax

Emerson Electric

Etsy

Alphabet

Harley-Davidson

Honeywell

Intercontinental Exchange

International Flavors & Fragrances

Intuit

Jack Henry & Associates

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map

There's no denying that Gilead Sciences, Inc. made some poor acquisition choices in the past. However, the cost is gone and the cash flow should come. The company accomplished its pipeline goals for 2022 and has lofty goals for 2023 that we expect will help support additional shareholder returns. Share buybacks and dividends could help returns.

Gilead Sciences: Don't Be Scared Post Run-Up

Pfizer

Blue chip dividend stocks rarely trade at a discount. Gilead Sciences and Pfizer are two exceptions to this general rule of thumb.

Is It Time to Buy These Ultra-Cheap Dividend Stocks?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body's anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, today announced that Pionyr and Gilead Sciences, Inc. (Nasdaq: GILD) have mutually agreed to change their 2020 exclusive option agreements.

Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement

Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.

Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother's Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative.

Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

Alibaba

Alibaba is coming off an encouraging quarter, and there are more opportunities for it to get stronger. Comcast is a diversified business that should be in a good position to continue performing well.

A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today

Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.

Gilead (GILD) Exercises Option to License Nurix's Candidate

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study.

Kite's Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

Nurix Therapeutics, Inc

Shares of Nurix Therapeutics Inc. NRIX, -0.99% gained about 6% in premarket trading on Monday after Gilead Sciences Inc. GILD, -3.18% said it exercised the option to exclusively license Nurix's targeted protein degrader molecule, which is being considered as a tool to treat inflammatory conditions like rheumatoid arthritis. Per the terms, Gilead will pay $20 million upfront, with an additional $425 million in potential milestone payments.

Nurix's stock rallies on Gilead's option

FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX‑0479.

Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

Amgen

Diamondback Energy

Kraft Heinz

Walgreens

The Nasdaq had a dreadful 2022, down a stunning 33% for the year. While the tech-heavy index has started off 2023 much better, up 5.9% as of the close Thursday, many investors are extremely nervous, especially given the recent uncertainty with the banking industry.

The 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Spring Break Rally

Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.

Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?

Gilead Sciences, Inc. (NASDAQ:GILD ) Barclays 2023 Global Healthcare Conference March 15, 2023 10:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Carter Gould - Barclays Carter Gould Good morning, and welcome to day two of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst.

Gilead Sciences, Inc. (GILD) Presents at Barclays 2023 Global Healthcare Conference (Transcript)

If one were to assume no growth, Gilead is trading at a wider discount to value than either AbbVie or Amgen. By purchasing a stock at a no-growth price, the investor need not make assumptions about the growth prospects of a particular company. Any realized growth is a bonus.

Assuming No-Growth, Gilead Is The Safest Choice Among The Large Biotechs

Ameren

Federal Agricultural

Albemarle

Allegion

C&F Financial

Cincinnati Financial

Canadian Natural Resources

CSG Systems International

Capital Southwest

Enterprise Financial Services

Extra Space Storage

First Financial Northwest

Franco-Nevada C

iShares Cohen & Steers REIT ETF

Coca-Cola

Merchants Bancorp

NorthWestern

NXP Semiconductors

Universal Display

Prologis

Douglas Dynamics

RCI Hospitality

All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 8.1% and a median increase of 6.8%.

37 Upcoming Dividend Increases, Including 2 Dividend Kings

Gilead Sciences got very lucky with its Veklury anti-viral, as it proved very valuable in combating Covid-19. Meanwhile, Gilead management has been working to transform the business from a declining cash cow into a biotech with growth prospects.

Gilead Sciences: Underlying Growth Obscured By Veklury Swings

Adobe

Cisco Systems

Dominion Energy

Guidewire Software

Johnson & Johnson

U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map

Gilead Sciences, Inc. (NASDAQ:GILD ) Cowen 43rd Annual Healthcare Conference March 7, 2023 11:10 AM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Is this slide over?

Gilead Sciences, Inc. (GILD) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)

Chevron

Monster Beverage

Marathon Petroleum

Taiwan Semiconductor Manufacturing

Unilever

While it's generally good to be optimistic, in the market, it also pays to be realistic, thus incentivizing consideration for cash-rich stocks to buy. Here, we're not necessarily talking about the most exciting ventures available.

7 Cash-Rich Companies to Invest in During Economic Uncertainty

News for Gilead Sciences Stock (GILD)